Sunkyu Kim
Vice President @Incyte
Signup · Get unlimited contacts
WORK HISTORY
Vice President @Incyte
Accountable for Incyte drug discovery programs in both small molecules and biologics. Key member of the scientific leadership driving translational science/early-late development strategies, business development opportunities and corporate innovation- Lead in-vitro/in-vivo pharmacology and target discovery groups for both targeted therapy and immuno-oncology. Have achieved multiple IND filings with some featured at major scientific conferences/press releases. Key driver for next generation therapies, including molecular glues, ADCs, bi-specifics and AI designed inhibitors- Responsible for major industry and academic collaborations, such as those with glue/AI companies and Broad institute/MIT-Harvard. One of the main contributors when evaluating partnership/acquisition opportunities in business development calls. Provide scientific updates to executive team/board members and represent the company in external scientific conferences/media events.
EDUCATION
The Johns Hopkins University School of Medicine
Postdoctoral fellowship
University at Buffalo
Doctor of Philosophy (PhD), Biological Sciences
SKILLS
ABOUT SUNKYU KIM
Creative drug discovery executive with a proven track record of growing the entire enterprise. Robust leader in both discovery and development, with accomplishments that include a FDA approved drug (Kisqali/Ribociclib),>15 INDs, biomarker driven clinical trials and biotech fund raising/acquisitions- At Incyte, I oversee the discovery unit responsible from target identification to IND submission in both small molecules and biologics. Some notable products are the inhibitors of; CDK2, KRAS G12D, JAK2/V617F and DGK to name a few. In addition to traditional small molecules and antibodies, I also lead efforts in molecular glues, ADCs/Bi-specifics, and AI driven drug design. As a member of the scientific leadership, I play key roles in translational science studies, early-late development clinical trials, business development opportunities and corporate innovation strategy- At Novartis, started the CDK4/6 program and led the Kisqali discovery team (approved for ER+/HER2- breast cancer). Served as a group leader accountable for many well known programs, including BRAF/MEK/SHP2 inhibitors, ER antagonists/SERDs, and chemical biology programs targeting high unmet needs such as refractory prostate cancer- At FORMA therapeutics, led the protein homeostasis franchise, covering oncology, non-oncology hematology and neuroscience. Some notable programs include deubiquitinase inhibitors, NASH, PKR activator and novel targets in Parkinson\'s disease. Made key contributions to company funding raising, building corporate strategy and board updates- Skilled communicator who can reach a wide range of audiences, including board members, executive teams, investors and the public. Effective team leader experienced in managing large teams and developing the next generation talents. Highly creative and ability to thrive in diverse business settings with a demonstrated leadership in large pharma employees), a small biotech (100 employees) and mid-size biotech employees).
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.